The company has reportedly commenced putting in place the people and locations necessary for the next phase 2b prostate cancer trial, to go off either year end or early 2017. However they have also done some things, such as paying off a loan early, where they were penalized for doing so, and adding a new board member, so we may be led to believe that the chances of a buy-out are very much alive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.